Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Medical System HoldingsCHSYF +0.11%87 Median PS Value is $1.76 as of Jul. 30, 2026, which is 220% above its 10-year median of 0.55. GuruFocus rates CHSYF with a GF Score™ of 87/100 and a GF Value™ of $1.30 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 546 Drug Manufacturers companies, China Medical System Holdings ranks worse than 52.38% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for China Medical System Holdings's Median PS Value or its related term are showing as below:
CHSYF'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.39 Med: 0.55 Max: 0.95
Current: 0.89
During the past 13 years, the highest Price to Median PS Value of China Medical System Holdings was 0.95. The lowest was 0.39. And the median was 0.55.
CHSYF's Price-to-Median-PS-Value is ranked worse than 52.38% of 546
companies
in the Drug Manufacturers industry
Industry Median: 0.87
vs CHSYF: 0.89
China Medical System Holdings (OTCPK:CHSYF) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
China Medical System Holdings's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
1.57
/
1.76
=
0.89
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Medical System Holdings Median PS Value Related Terms
China Medical System Holdings Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Medical System Holdings Median PS Value Chart
For the Drug Manufacturers - Specialty & Generic subindustry, China Medical System Holdings's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Medical System Holdings Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Medical System Holdings's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where China Medical System Holdings's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 3.7053.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China Medical System Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.475.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Medical System Holdings (CHSYF) has a Median PS Value of $1.76 as of Jul. 30, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on China Medical System Holdings and its competitors. This is 220% above median its historical median of 0.55. Over the past decade, China Medical System Holdings' Median PS Value has ranged from 0.39 to 0.95. According to the industry distribution chart, China Medical System Holdings ranks #286 out of 546 companies in the Drug Manufacturers industry, placing it in the top 52.4%.
Is China Medical System Holdings' Median PS Value too high?
China Medical System Holdings' current Median PS Value of $1.76 is 220% above median its 10-year median of 0.55. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 0.95. The Drug Manufacturers industry median Median PS Value is 0.87. China Medical System Holdings' value of $1.76 is 102.3% above this industry median. Based on the distribution chart, China Medical System Holdings ranks #286 out of 546 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, China Medical System Holdings has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Medical System Holdings' Median PS Value compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Medical System Holdings ranks #286 out of 546 companies for Median PS Value. This places China Medical System Holdings in the lower half of its industry. The industry median Median PS Value is 0.87. China Medical System Holdings' value of $1.76 is 102.3% above this benchmark. Historically, China Medical System Holdings' own Median PS Value has ranged from 0.39 to 0.95 over the past decade. While the company's 10-year median is 0.55 vs. the industry median of 0.87, China Medical System Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.87, based on 546 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Medical System Holdings's current Median PS Value of $1.76 is 102.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on China Medical System Holdings and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Medical System Holdings's current Median PS Value is $1.76, which is 220% above median its own 10-year median of 0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Medical System Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Medical System Holdings (CHSYF) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.30, compared to a current price of $1.57 — trading 20.8% above its estimated fair value. The current Median PS Value is $1.76, which is 220% above median its 10-year median of 0.55 and 102.3% above the Drug Manufacturers industry median of 0.87. China Medical System Holdings' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For China Medical System Holdings (CHSYF), the current Median PS Value is $1.76 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Medical System Holdings (CHSYF) Overvalued in 2026?
Based on GuruFocus' analysis, China Medical System Holdings stock appears to be overvalued.
The current stock price of $1.57 is trading 20.8% above its estimated GF Value™ of $1.30.
GuruFocus considers China Medical System Holdings to be Modestly Overvalued.
Key valuation signals for CHSYF:
Median PS Value: $1.76 (220% above median its 10-year median of 0.55)
GF Value™: $1.30 vs. price of $1.57 (20.8% above fair value)
Industry Position: 102.3% above the Drug Manufacturers median (#286 of 546)
No single metric tells the full story. See the CHSYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Medical System Holdings Business Description
China Medical System Holdings Ltd is a holding company. Along with its subsidiaries, it is engaged in the research and development, production, promotion and sale of medicines. The company's reportable segments are: (i) Integrated pharmaceuticals portfolio and (ii) Skin diseases related business. The majority of the company's revenue, which consists of pharmaceutical products sales, is derived from the integrated pharmaceuticals portfolio segment.
87GF Score
Get the complete analysis for CHSYF
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHSYF has been successfully added to your 
